

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 4, 2023

DRAFT QUESTIONS

NDA 215500

eflornithine tablets (DFMO)

Applicant: US WorldMeds

PROPOSED INDICATION:

- to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma who have completed multiagent, multimodality therapy.
-

1. **DISCUSSION:** Discuss the strengths and limitations of the externally controlled trial results to support the use of DFMO in pediatric patients with high-risk neuroblastoma.
2. **DISCUSSION:** Discuss the strengths and limitations of the additional nonclinical and clinical data to support the use of DFMO in pediatric patients with high-risk neuroblastoma.
3. **VOTE:** Has the Applicant provided sufficient evidence to conclude that DFMO improves event-free survival in patients with high-risk neuroblastoma?